JOSD2 and non-small cell lung carcinoma: Collectively, we identified HY041004 as a novel small-molecule inhibitor for JOSD2 and confirmed its pharmacological inhibitory effect both in vitro/vivo, providing a viable therapeutic strategy in NSCLC patients by targeting JOSD2 with inhibitors (Fig. 8e).